Videos

Evan Y. Yu, MD, discusses the case and subsequent palliative treatment plan for a patient with metastatic castration-resistant prostate cancer.

Jennifer Marie Suga, MD, discusses implementing a genomic oncology program at Kaiser Permanente Northern California through large-scale genomic next generation sequencing testing of patients with advanced cancers in the community setting.

Yeon Hee Park, MD, discusses the data supporting the FDA’s accelerated approval of fam-trastuzumab deruxtecan-nxki for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received ≥2 prior anti–HER2-based regimens in the metastatic setting.

How the recent FDA approval of the subcutaneous formulation of daratumumab in multiple myeloma will affect patients and oncologists from practical and clinical standpoints.

Mansoor Raza Mirza, MD, discusses the final survival data from the randomized phase 2 NSGO-AVANOVA2/ENGOT-OV24 study, which evaluated the combination or niraparib plus bevacizumab versus niraparib alone in recurrent platinum-sensitive ovarian cancer.

Mark M. Awad, MD, PhD, discusses the characterization of patients with non–small cell lung cancer who have MET exon 14 skipping alterations and potential acquired resistance mechanisms.

David O'Malley, MD, discusses the role of PARP inhibitors in the treatment landscape of ovarian cancer.

Ramez Eskander, MD, presents the case of a 68-year-old woman with stage IV ovarian cancer, and discusses the management approach for this patient and similar cases.

Brian M. Slomovitz, MD, discusses the some of the subcategories of endometrial cancer and how the make a difference for patients’ treatment.

Yousef Zakharia, MD, discusses the next steps after the phase 1 trial of seleno-L-methionine in combination with axitinib as treatment of adult patients with previously treated or relapsed clear cell renal cell carcinoma.

Winston Tan, MD, discusses 2 agents that have advanced the treatment landscape for patients with thyroid cancer, including the multi-tyrosine kinase inhibitor lenvatinib and another TKI, sorafenib.